CN1705662B - 埃坡霉素b的制备、分离和纯化的方法,及埃坡霉素b的x-射线晶体结构 - Google Patents
埃坡霉素b的制备、分离和纯化的方法,及埃坡霉素b的x-射线晶体结构 Download PDFInfo
- Publication number
- CN1705662B CN1705662B CN038226626A CN03822662A CN1705662B CN 1705662 B CN1705662 B CN 1705662B CN 038226626 A CN038226626 A CN 038226626A CN 03822662 A CN03822662 A CN 03822662A CN 1705662 B CN1705662 B CN 1705662B
- Authority
- CN
- China
- Prior art keywords
- epothilone
- solvent
- solvate
- resin
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 title claims abstract description 225
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 title claims abstract description 214
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 title claims abstract description 210
- 238000000034 method Methods 0.000 title claims abstract description 68
- 238000002360 preparation method Methods 0.000 title claims description 31
- 238000000746 purification Methods 0.000 title abstract description 7
- 238000002955 isolation Methods 0.000 title abstract 3
- 239000013078 crystal Substances 0.000 title description 24
- 229920005989 resin Polymers 0.000 claims abstract description 69
- 239000011347 resin Substances 0.000 claims abstract description 69
- 238000000855 fermentation Methods 0.000 claims abstract description 25
- 230000004151 fermentation Effects 0.000 claims abstract description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 257
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 207
- 229930189413 Esperamicin Natural products 0.000 claims description 54
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 claims description 54
- 239000002904 solvent Substances 0.000 claims description 48
- 239000012453 solvate Substances 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 21
- 230000008569 process Effects 0.000 claims description 17
- 241000862997 Sorangium cellulosum Species 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 13
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- 239000002798 polar solvent Substances 0.000 claims description 4
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 3
- 238000000638 solvent extraction Methods 0.000 claims description 3
- 239000011877 solvent mixture Substances 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims 2
- 239000003674 animal food additive Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 20
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 235000019439 ethyl acetate Nutrition 0.000 description 89
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 63
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- 239000000203 mixture Substances 0.000 description 37
- 239000002002 slurry Substances 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 36
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 36
- 238000002425 crystallisation Methods 0.000 description 33
- 230000008025 crystallization Effects 0.000 description 32
- 229930013356 epothilone Natural products 0.000 description 31
- 238000005406 washing Methods 0.000 description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- 238000000634 powder X-ray diffraction Methods 0.000 description 27
- 230000001580 bacterial effect Effects 0.000 description 23
- 239000007787 solid Substances 0.000 description 23
- 239000012065 filter cake Substances 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000001914 filtration Methods 0.000 description 17
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 16
- 235000010334 sodium propionate Nutrition 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000004324 sodium propionate Substances 0.000 description 15
- 229960003212 sodium propionate Drugs 0.000 description 15
- 238000001291 vacuum drying Methods 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 235000015097 nutrients Nutrition 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 238000001816 cooling Methods 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- 238000000926 separation method Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 239000002054 inoculum Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 230000001954 sterilising effect Effects 0.000 description 12
- 238000004659 sterilization and disinfection Methods 0.000 description 12
- UKIMCRYGLFQEOE-RLHMMOOASA-N (-)-Epothilone F Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(CO)sc2)/C)OC(=O)C[C@H](O)C1(C)C UKIMCRYGLFQEOE-RLHMMOOASA-N 0.000 description 11
- UKIMCRYGLFQEOE-UHFFFAOYSA-N Epothilone F Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC2(C)OC2CC1C(C)=CC1=CSC(CO)=N1 UKIMCRYGLFQEOE-UHFFFAOYSA-N 0.000 description 11
- 239000013530 defoamer Substances 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- UKIMCRYGLFQEOE-RGJAOAFDSA-N epothilone f Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(CO)=N1 UKIMCRYGLFQEOE-RGJAOAFDSA-N 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 11
- 238000009413 insulation Methods 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- 230000003278 mimic effect Effects 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- -1 lactone compounds Chemical class 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 8
- 239000012296 anti-solvent Substances 0.000 description 8
- 239000012535 impurity Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000012452 mother liquor Substances 0.000 description 8
- 235000019260 propionic acid Nutrition 0.000 description 8
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 8
- 235000020183 skimmed milk Nutrition 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- WTLKTXIHIHFSGU-UHFFFAOYSA-N 2-nitrosoguanidine Chemical compound NC(N)=NN=O WTLKTXIHIHFSGU-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 238000013375 chromatographic separation Methods 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000013557 residual solvent Substances 0.000 description 5
- 239000010458 rotten stone Substances 0.000 description 5
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 5
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 4
- 238000003810 ethyl acetate extraction Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 4
- 235000019799 monosodium phosphate Nutrition 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 4
- CGZDWVZMOMDGBN-UHFFFAOYSA-N 2-Ethylthiazole Chemical class CCC1=NC=CS1 CGZDWVZMOMDGBN-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003518 caustics Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 238000001144 powder X-ray diffraction data Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000003885 epothilone B derivatives Chemical class 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000013411 master cell bank Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 150000002916 oxazoles Chemical class 0.000 description 2
- 150000003016 phosphoric acids Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LOVKLTIBMZTDQA-UHFFFAOYSA-N 2-ethyl-1,3-thiazole;1,3-oxazole Chemical compound C1=COC=N1.CCC1=NC=CS1 LOVKLTIBMZTDQA-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- XOZIUKBZLSUILX-CIPHLLOYSA-N CC(CCC/C(/C)=C\C[C@@H](/C(/C)=C/c1c[s]c(C)n1)OC(C[C@@H](C(C)(C)C(C1C)=O)O)=O)[C@@H]1O Chemical compound CC(CCC/C(/C)=C\C[C@@H](/C(/C)=C/c1c[s]c(C)n1)OC(C[C@@H](C(C)(C)C(C1C)=O)O)=O)[C@@H]1O XOZIUKBZLSUILX-CIPHLLOYSA-N 0.000 description 1
- 0 CC(CCC[C@](C)(CC[C@](*C(C[C@@](C(C)(C)C(C1C)=O)O)=O)C(C)=Cc2c[s]c(C)n2)O)[C@@]1O Chemical compound CC(CCC[C@](C)(CC[C@](*C(C[C@@](C(C)(C)C(C1C)=O)O)=O)C(C)=Cc2c[s]c(C)n2)O)[C@@]1O 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical class ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical class C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910003091 WCl6 Inorganic materials 0.000 description 1
- QRSFFHRCBYCWBS-UHFFFAOYSA-N [O].[O] Chemical compound [O].[O] QRSFFHRCBYCWBS-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- XZKRXPZXQLARHH-UHFFFAOYSA-N buta-1,3-dienylbenzene Chemical compound C=CC=CC1=CC=CC=C1 XZKRXPZXQLARHH-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- PMPYSSMGWFNAAQ-UHFFFAOYSA-N dichloromethane;n,n-diethylethanamine Chemical compound ClCCl.CCN(CC)CC PMPYSSMGWFNAAQ-UHFFFAOYSA-N 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229940017219 methyl propionate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- CZFNISFYDPIDNM-UHFFFAOYSA-N n,n-dimethylformamide;oxolane Chemical compound CN(C)C=O.C1CCOC1 CZFNISFYDPIDNM-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000004476 plant protection product Substances 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 239000012985 polymerization agent Substances 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- WPKVKNZNPQRHOD-UHFFFAOYSA-N prop-1-ene Chemical compound [CH2+]C=C WPKVKNZNPQRHOD-UHFFFAOYSA-N 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009288 screen filtration Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- KPGXUAIFQMJJFB-UHFFFAOYSA-H tungsten hexachloride Chemical compound Cl[W](Cl)(Cl)(Cl)(Cl)Cl KPGXUAIFQMJJFB-UHFFFAOYSA-H 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/14—Nitrogen or oxygen as hetero atom and at least one other diverse hetero ring atom in the same ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/181—Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组分 | 优选(g/L) | 更优选(g/L) | 更更优选(g/L) |
脱脂乳粉 | 0.5-12 | 1-8 | 2-6 |
烤Nutrisoy粉1 | 0.5-12 | 1-8 | 2-6 |
Tastone-1541 | 0.5-12 | 1-6 | 1-4 |
Maltrin-M0401 | 4-18 | 6-14 | 8-12 |
CaCl2·2H2O | 0.2-2.4 | 0.4-1.6 | 0.8-1.2 |
MgSO4·7H2O | 0.2-2.4 | 0.4-1.6 | 0.8-1.2 |
EDTA,Felll,Na盐 | 0.002-0.02 | 0.004-0.016 | 0.006-0.014 |
HEPES | 6-20 | 8-16 | 10-14 |
甘油 | 0.5-12 | 1-8 | 2-6 |
组分 | 优选(g/L) | 更优选(g/L) | 更更优选(g/L) |
甘油 | 2-20 | 4-16 | 6-14 |
树脂 | 10-40 | 12-35 | 15-30 |
组分 | 优选(%) |
丙酸钠 | 2-5 |
Maltrin-M040 | 8-12 |
Tastone-154 | 2-5 |
组分 | 优选(%) |
磷酸二钠 | 1.0-2.0 |
磷酸一钠 | 0.3-0.7 |
组分 | 优选(g/L) | 更优选(g/L) | 更更优选(g/L) |
消泡剂 | 0.5-5 | 1-4.5 | 1.5-4 |
组分 | 优选(g/L) | 更优选(g/L) | 更更优选(g/L) |
树脂 | 10-50 | 12-45 | 15-40 |
组分 | 优选(g/L) |
Tastone-154 | 15-25 |
Maltrin-M040 | 55-75 |
消泡剂 | 0.5-1.5 |
组分 | 优选(g/L) |
脱脂乳粉 | 40-60 |
Maltrin-M040 | 140-180 |
甘油 | 60-90 |
消泡剂 | 0.5-1.5 |
晶形 | |
epoB-TOβ | 按实施例8A的描述从甲苯中结晶 |
epoB-ANβ | 按实施例8B的描述从乙腈中结晶 |
epoB-EAβ | 按实施例8C的描述从乙酸乙酯(ETOAc)中结晶 |
epoB-IPβ | 按实施例8D的描述从异丙醇(IPA)中结晶 |
组分 | g/L |
脱脂乳粉 | 4 |
烤Nutrisoy粉 | 4 |
Tastone-154 | 2 |
Maltrin-M180 | 10 |
CaCl2·2H2O | 1 |
MgSO4·7H2O | 1 |
EDTA,Felll,Na盐 | 0.008 |
HEPES | 12 |
甘油 | 4.3 |
组分 | g/L |
脱脂乳粉 | 4 |
烤Nutrisoy粉 | 4 |
Tastone-154 | 2 |
Maltrin-M040 | 10 |
CaCl2·2H2O | 1 |
MgSO4·7H2O | 1 |
EDTA,Felll,Na盐 | 0.008 |
HEPES | 12 |
甘油 | 10 |
XAD-16resin | 16 |
F1阶段 | 将取自两个冷冻小瓶中的3.0mL等分试样接种到250mL烧瓶内的90mL培养基E中并使其在30℃和160rpm下生长4-8小时。 |
F2阶段 | 将20mL(10%)F1阶段的细胞转入500mL烧瓶内的180mL培养基E中并在30℃和160rpm下保温2-4天。 |
F3阶段 | 重复F2阶段步骤以增加接种物数量。将20mLF2阶段的接种物转入各装有180mL培养基E的6-8×500mL烧瓶中并在30℃和160rpm下保温2-4天。 |
F4阶段 | 将120mL(10%)F3阶段的培养物转入4L抽气瓶内的1080mL培养基E中,然后在30℃和160rpm下保温2-4天。 |
F1至F4 | 14L | |
温度 | 30℃ | 32℃ |
压力 | 10psi | |
气流 | 0.25vvm | |
pH | 7.2-7.4 | |
DO | 20-40% | |
叶轮直径(英寸) | 3.3-4.2 | |
端速(m/s) | 1.3-2.2 | |
进端灭菌时间 | 60min | |
培养基灭菌时间 | 30min | 60min |
树脂 | 15-30g/L |
营养物进料组合物: | 在5L的瓶内配制含4.1%Maltrin-M040和1.3%Tastone-154的溶液。将进料在121℃下灭菌60分钟。 |
营养物进料速度: | 进料速度为6mL/小时。 |
丙酸钠进料: | 将5.0%丙酸钠(1.5L在2L的瓶内)在121℃下灭菌60分钟。 |
丙酸钠进料速度: | 从24-48小时开始至结束,2Ml/小时。调整进料速度以将丙酸钠浓度维持在0.05-0.2mg/mL之间(HPLC分析)。 |
组分 | g/L |
脱脂乳粉(或豆蛋白浓度) | 5 |
烤Nutrisoy粉 | 5 |
Tastone-154 | 2.5 |
Maltrin-M040 | 12.3 |
CaCl2·2H2O | 1.2 |
MgSO4·7H2O | 1.2 |
EDTA,Felll,Na盐 | 0.012 |
甘油 | 5.4 |
消泡剂 | 2.5 |
压力:8-12psig温度:30-33℃搅拌器轴转速:50-60rpm | 气流:0.5-0.7wmpH:7.1-7.3 |
组分 | 量 |
洗过的XAD-16树脂 | 15-40g/L |
组分 | 重量(kg) |
脱脂乳粉 | 130 |
烤Nutrisoy粉 | 130 |
Tastone-154 | 65 |
Maltrin-M040 | 238 |
CaCl2·2H2O | 21.6 |
MgSO4·7H2O | 21.6 |
EDTA,Felll,Na盐 | 0.22 |
甘油 | 216 |
消泡剂 | 54 |
组分 | g/L |
Tastone-154 | 20 |
Maltrin-M040 | 66 |
消泡剂 | 1.0 |
组分 | g/L |
脱脂乳粉 | 49 |
Maltrin-M040 | 154 |
Tastone-154 | 20 |
甘油 | 78 |
消泡剂 | 1.6 |
进料重(g) | 分析(gepo B/Kg) | epo B进料(g) | 原始滤饼中的Epo B(g) | %回收率 |
1327-1391 | 4.4-12.2 | 6.0-16.5 | 5.5-13.6 | 87-98 |
Claims (7)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41299402P | 2002-09-23 | 2002-09-23 | |
US60/412,994 | 2002-09-23 | ||
PCT/US2003/029628 WO2004026254A2 (en) | 2002-09-23 | 2003-09-22 | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100890450A Division CN101050445B (zh) | 2002-09-23 | 2003-09-22 | 产埃坡霉素的微生物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1705662A CN1705662A (zh) | 2005-12-07 |
CN1705662B true CN1705662B (zh) | 2011-07-06 |
Family
ID=32030950
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN038226626A Expired - Fee Related CN1705662B (zh) | 2002-09-23 | 2003-09-22 | 埃坡霉素b的制备、分离和纯化的方法,及埃坡霉素b的x-射线晶体结构 |
CN2007100890450A Expired - Fee Related CN101050445B (zh) | 2002-09-23 | 2003-09-22 | 产埃坡霉素的微生物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100890450A Expired - Fee Related CN101050445B (zh) | 2002-09-23 | 2003-09-22 | 产埃坡霉素的微生物 |
Country Status (23)
Country | Link |
---|---|
US (4) | US7172884B2 (zh) |
EP (3) | EP1542998A4 (zh) |
JP (2) | JP4523843B2 (zh) |
KR (2) | KR20050053681A (zh) |
CN (2) | CN1705662B (zh) |
AU (1) | AU2003275068B2 (zh) |
BR (1) | BRPI0314133A8 (zh) |
CA (3) | CA2695720C (zh) |
CO (1) | CO5540384A2 (zh) |
ES (2) | ES2439995T3 (zh) |
GE (1) | GEP20074017B (zh) |
HK (1) | HK1113387A1 (zh) |
HR (1) | HRP20050278A2 (zh) |
IL (2) | IL222455A0 (zh) |
IS (1) | IS7768A (zh) |
MX (1) | MXPA05003006A (zh) |
NO (1) | NO334167B1 (zh) |
PL (1) | PL375902A1 (zh) |
RS (1) | RS20050235A (zh) |
RU (1) | RU2368661C2 (zh) |
TW (1) | TWI291464B (zh) |
WO (1) | WO2004026254A2 (zh) |
ZA (1) | ZA200501680B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106834377A (zh) * | 2017-03-07 | 2017-06-13 | 鲁南制药集团股份有限公司 | 一种生产埃博霉素b的方法 |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100344627C (zh) | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用 |
WO1999001124A1 (en) | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
CN1774253A (zh) | 2001-02-20 | 2006-05-17 | 布里斯托尔-迈尔斯斯奎布公司 | 用环氧丙酯酮衍生物治疗顽固性肿瘤 |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
PT1767535E (pt) | 2002-08-23 | 2010-02-24 | Sloan Kettering Inst Cancer | Síntese de epotilonas, respectivos intermediários, análogos e suas utilizações |
EP1542998A4 (en) * | 2002-09-23 | 2007-01-31 | Bristol Myers Squibb Co | PROCESS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILON B, AND RINSE CRYSTAL STRUCTURES OF EPOTHILON B |
US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
US20090004277A1 (en) * | 2004-05-18 | 2009-01-01 | Franchini Miriam K | Nanoparticle dispersion containing lactam compound |
AU2006336468B2 (en) | 2005-02-11 | 2012-04-12 | University Of Southern California | Method of expressing proteins with disulfide bridges |
RU2449788C2 (ru) * | 2006-04-05 | 2012-05-10 | Новартис Аг | Комбинации терапевтических агентов для лечения рака |
US8008256B2 (en) * | 2006-05-01 | 2011-08-30 | University Of Southern California | Combination therapy for treatment of cancer |
NZ574194A (en) * | 2006-08-16 | 2011-12-22 | Novartis Ag | Crystal form of epothilone b and use in pharmaceutical compositions |
CN101918400B (zh) * | 2008-02-01 | 2012-08-29 | 浙江海正药业股份有限公司 | 一种分离和提纯埃博霉素的方法 |
WO2009132253A1 (en) | 2008-04-24 | 2009-10-29 | Bristol-Myers Squibb Company | Use of epothelone d in treating tau-associated diseases including alzheimer's disease |
US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
KR101372563B1 (ko) * | 2011-12-26 | 2014-03-14 | 주식회사 삼양바이오팜 | 에포틸론 함유물질로부터 에포틸론 a와 b의 추출 및 정제 방법 |
CN103183681B (zh) * | 2013-03-06 | 2016-01-13 | 浙江海正药业股份有限公司 | 伊沙匹隆的新晶型及其制备方法 |
WO2015024883A1 (en) * | 2013-08-19 | 2015-02-26 | Sandoz Ag | Method for the purification of epothilones via crystallization |
WO2015024884A1 (en) * | 2013-08-19 | 2015-02-26 | Sandoz Ag | Method for the purifiction of epothilones via crystallization |
CN104046579B (zh) * | 2014-05-16 | 2016-09-21 | 虞龙 | 一株埃博霉素高产菌及其在发酵产埃博霉素中的应用 |
CN106905338B (zh) * | 2017-03-07 | 2020-06-23 | 鲁南制药集团股份有限公司 | 一种埃博霉素b的提纯方法 |
CN107827943B (zh) * | 2017-11-28 | 2022-06-10 | 绍兴厚普生物科技有限责任公司 | 一种从发酵液中提取胞嘧啶核苷的方法 |
CN110964029B (zh) * | 2019-12-19 | 2020-11-03 | 鲁南制药集团股份有限公司 | 一种埃博霉素b发酵液的预处理方法 |
KR102440644B1 (ko) * | 2020-05-28 | 2022-09-05 | 공주대학교 산학협력단 | 파클리탁셀 정제 시 가스 버블을 이용한 분별침전방법 |
CN112457320A (zh) * | 2020-11-30 | 2021-03-09 | 湖北宏中药业股份有限公司 | 一种提高伊沙匹隆合成反应速率的方法 |
CN112409369B (zh) * | 2020-11-30 | 2023-03-28 | 湖北宏中药业股份有限公司 | 一种埃博霉素b的高效提取纯化方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1237970A (zh) * | 1996-11-18 | 1999-12-08 | 生物技术研究有限公司(Gbf) | Epothilone C、D、E和F,其制备方法,以及作为细胞抑制剂和植物保护剂的应用 |
US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
WO2002046196A1 (en) * | 2000-12-07 | 2002-06-13 | Novartis Ag | Process for the isolation and purification of epothilones |
CN1369484A (zh) * | 2002-02-07 | 2002-09-18 | 山东大学 | 一种从粘细菌发酵液中分离提纯埃博霉素的方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE879605C (de) | 1951-08-05 | 1953-06-15 | Leitz Ernst Gmbh | Optisches Instrument mit gekuppeltem Objektiv- und Kondensor-Wechsler |
DE3669515D1 (de) * | 1985-09-13 | 1990-04-19 | Biotechnolog Forschung Gmbh | Makrozyklische antibiotika. |
DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
JP4183099B2 (ja) * | 1995-11-17 | 2008-11-19 | ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) | エポチロンcおよびd、製造法ならびに組成物 |
DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
DE19542986A1 (de) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
JP2001500851A (ja) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | エポシロンの製造法および製造過程中に得られる中間生産物 |
DE19636343C1 (de) | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
WO1999001124A1 (en) * | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
CZ298027B6 (cs) | 1997-02-25 | 2007-05-30 | Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf) | Zpusob prípravy epothilon-N-oxidu a N-oxidy epothilonu |
DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
EP0975622B1 (de) | 1997-04-18 | 2002-10-09 | Studiengesellschaft Kohle mbH | Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium |
DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
ES2184307T3 (es) | 1997-07-16 | 2003-04-01 | Schering Ag | Derivados de tiazol, procedimiento para su preparacion y su utilizacion. |
AU9340998A (en) | 1997-08-09 | 1999-03-01 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
US6320045B1 (en) * | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
AR017979A1 (es) | 1998-02-05 | 2001-10-24 | Novartis Ag | Formulaciones farmaceuticas de epotilonas, metodo para su preparacion y el uso de los mismos para la manufactura de un medicamento |
IL138113A0 (en) | 1998-02-25 | 2001-10-31 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereto and analogues thereof |
FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
FR2776071B1 (fr) * | 1998-03-13 | 2000-05-26 | Eastman Kodak Co | Dispositif de mesure automatique de la concentration d'un agent developpateur |
US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
WO2000000485A1 (de) | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung |
KR100716272B1 (ko) * | 1998-11-20 | 2007-05-09 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
EP1140944B1 (en) | 1998-12-22 | 2003-08-27 | Novartis AG | Epothilone derivatives and their use as antitumor agents |
CA2356360A1 (en) | 1998-12-23 | 2000-07-06 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
KR100718616B1 (ko) | 1999-02-18 | 2007-05-16 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 16-할로겐-에포틸론 유도체, 그 제조 방법 및 제약학적 용도 |
NZ513629A (en) * | 1999-02-22 | 2004-01-30 | Bristol Myers Squibb Co | C-21 modified epothilones |
US6211412B1 (en) * | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
PE20010116A1 (es) | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
TW200303202A (en) * | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
EP1542998A4 (en) * | 2002-09-23 | 2007-01-31 | Bristol Myers Squibb Co | PROCESS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILON B, AND RINSE CRYSTAL STRUCTURES OF EPOTHILON B |
-
2003
- 2003-09-22 EP EP03759335A patent/EP1542998A4/en not_active Withdrawn
- 2003-09-22 RU RU2005112443/13A patent/RU2368661C2/ru not_active Application Discontinuation
- 2003-09-22 CA CA2695720A patent/CA2695720C/en not_active Expired - Fee Related
- 2003-09-22 GE GEAP20038758A patent/GEP20074017B/en unknown
- 2003-09-22 PL PL03375902A patent/PL375902A1/xx not_active Application Discontinuation
- 2003-09-22 CN CN038226626A patent/CN1705662B/zh not_active Expired - Fee Related
- 2003-09-22 TW TW092126105A patent/TWI291464B/zh not_active IP Right Cessation
- 2003-09-22 BR BRPI0314133A patent/BRPI0314133A8/pt not_active Application Discontinuation
- 2003-09-22 WO PCT/US2003/029628 patent/WO2004026254A2/en active Application Filing
- 2003-09-22 EP EP10181230A patent/EP2287168B1/en not_active Expired - Lifetime
- 2003-09-22 CN CN2007100890450A patent/CN101050445B/zh not_active Expired - Fee Related
- 2003-09-22 MX MXPA05003006A patent/MXPA05003006A/es active IP Right Grant
- 2003-09-22 KR KR1020057004892A patent/KR20050053681A/ko not_active Application Discontinuation
- 2003-09-22 AU AU2003275068A patent/AU2003275068B2/en not_active Ceased
- 2003-09-22 US US10/668,032 patent/US7172884B2/en not_active Ceased
- 2003-09-22 CA CA2695671A patent/CA2695671A1/en not_active Abandoned
- 2003-09-22 ES ES10181150.3T patent/ES2439995T3/es not_active Expired - Lifetime
- 2003-09-22 EP EP10181150.3A patent/EP2280014B1/en not_active Expired - Lifetime
- 2003-09-22 ES ES10181230T patent/ES2405753T3/es not_active Expired - Lifetime
- 2003-09-22 RS YUP-2005/0235A patent/RS20050235A/sr unknown
- 2003-09-22 KR KR1020127014263A patent/KR101406635B1/ko active IP Right Grant
- 2003-09-22 JP JP2004538301A patent/JP4523843B2/ja not_active Expired - Fee Related
- 2003-09-22 CA CA2499600A patent/CA2499600C/en not_active Expired - Fee Related
-
2004
- 2004-03-22 US US10/805,724 patent/US7241899B2/en not_active Expired - Lifetime
-
2005
- 2005-02-14 IL IL222455A patent/IL222455A0/en not_active IP Right Cessation
- 2005-02-14 IL IL166868A patent/IL166868A/en not_active IP Right Cessation
- 2005-02-21 NO NO20050929A patent/NO334167B1/no not_active IP Right Cessation
- 2005-02-25 ZA ZA200501680A patent/ZA200501680B/xx unknown
- 2005-03-22 IS IS7768A patent/IS7768A/is unknown
- 2005-03-23 HR HR20050278A patent/HRP20050278A2/xx not_active Application Discontinuation
- 2005-03-23 CO CO05026479A patent/CO5540384A2/es unknown
-
2007
- 2007-01-31 US US11/669,268 patent/US7767432B2/en active Active
-
2008
- 2008-03-19 HK HK08103225.3A patent/HK1113387A1/xx not_active IP Right Cessation
-
2009
- 2009-08-06 US US12/462,816 patent/USRE42191E1/en active Active
- 2009-10-22 JP JP2009243115A patent/JP5193983B2/ja not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1237970A (zh) * | 1996-11-18 | 1999-12-08 | 生物技术研究有限公司(Gbf) | Epothilone C、D、E和F,其制备方法,以及作为细胞抑制剂和植物保护剂的应用 |
US6194181B1 (en) * | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
CN1291239A (zh) * | 1998-02-19 | 2001-04-11 | 诺瓦提斯公司 | 细胞抑制剂及其晶形的发酵制备方法 |
WO2002046196A1 (en) * | 2000-12-07 | 2002-06-13 | Novartis Ag | Process for the isolation and purification of epothilones |
CN1369484A (zh) * | 2002-02-07 | 2002-09-18 | 山东大学 | 一种从粘细菌发酵液中分离提纯埃博霉素的方法 |
Non-Patent Citations (2)
Title |
---|
李越中等.纤维堆囊菌Soce90菌株发酵合成新抗癌物质epothilones的营养控制.中国抗生素杂志23 6.1998,23(6),420-424. |
李越中等.纤维堆囊菌Soce90菌株发酵合成新抗癌物质epothilones的营养控制.中国抗生素杂志23 6.1998,23(6),420-424. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106834377A (zh) * | 2017-03-07 | 2017-06-13 | 鲁南制药集团股份有限公司 | 一种生产埃博霉素b的方法 |
CN106834377B (zh) * | 2017-03-07 | 2020-05-05 | 鲁南制药集团股份有限公司 | 一种生产埃博霉素b的方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1705662B (zh) | 埃坡霉素b的制备、分离和纯化的方法,及埃坡霉素b的x-射线晶体结构 | |
US6194181B1 (en) | Fermentative preparation process for and crystal forms of cytostatics | |
AU2003251902B2 (en) | Tiacumicin production | |
CN102586358B (zh) | 一种提高埃博霉素b产率的生物合成方法 | |
CN101495616A (zh) | 通过发酵生产法尼基化二苯并二氮杂酮的方法 | |
CN101323869A (zh) | 埃博霉素b内酰胺衍生物的制备方法 | |
CN113736835A (zh) | 红豆杉内生真菌突变体发酵产紫杉醇的工业化制备工艺 | |
CN113789357A (zh) | 组合发酵产虫草素和喷司他丁的工业化制备方法 | |
CN104805149A (zh) | 一种伊沙匹隆的半合成制备方法 | |
JPH06247971A (ja) | 血小板活性化因子拮抗物質フォマクチン類 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20051207 |
|
CI01 | Publication of corrected invention patent application |
Correction item: Rejection of patent application Correct: Dismiss False: Reject Number: 32 Volume: 26 |
|
ERR | Gazette correction |
Free format text: CORRECT: PATENT APPLICATION REJECTION AFTER PUBLICATION; FROM: REJECTION TO: REJECTION OF REVOCATION |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180504 Address after: New jersey, USA Patentee after: R- pharmaceutical American operations LLC Address before: New jersey, USA Patentee before: Bristol-Myers Squibb Co. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110706 |
|
CF01 | Termination of patent right due to non-payment of annual fee |